Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234550 | 0.87 | MEN1 (0.43) | SLC22A12MEN1KMT2ASGMS2CYP1A2 | |
| SCHEMBL1233581 | 0.79 | SLC22A12 (0.67) | SLC22A12CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1233631 | 0.77 | SLC22A12 (0.65) | SLC22A12MEN1KMT2ASGMS2CYP1A2 | |
| SCHEMBL2363566 | 0.74 | ABCB1 (0.43) | SLC22A12SGMS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1235314 | 0.74 | ABCB1 (0.43) | SLC22A12SGMS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3149895 | 0.74 | AR (0.47) | TSHRMAPK1TDP1 | |
| SCHEMBL1234559 | 0.73 | SLC22A12 (0.65) | SLC22A12 | |
| SCHEMBL17237601 | 0.72 | SMN1; SMN2 (0.48) | SLC22A12SGMS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1235279 | 0.71 | SGMS2 (0.42) | SLC22A12SGMS2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1235252 | 0.69 | ABCB1 (0.41) | SLC22A12MEN1KMT2ASGMS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2282736-B1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | claimed |
| US-8410154-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-04-02 | — | — | US | claimed |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-25 | — | — | US | claimed |
| EP-2282736-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-02-16 | — | — | EP | claimed |
| WO-2009134995-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-05 | — | — | WO | claimed |
| EP-2282736-B1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8889724-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889724-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130336949-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-19 | — | — | US | disclosed |
| US-8410154-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410154-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2282736-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009134995-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130336949-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | GLS, CASP1, PCSK9 | SLC22A12 637/4885MEN1 931/4885KMT2A 2070/4885 |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | FPR1, CASP1, PON1 | SLC22A12 1227/4885MEN1 1832/4885KMT2A 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.